This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Magnetization transfer imaging in premanifest and manifest huntington disease: a 2-year follow-up


van den Bogaard, S. J. A., Dumas, E. M., Hart, E. P., Milles, J., Reilmann, R., Stout, J. C., Craufurd, D., Gibbard, C. R., Tabrizi, S. J., van Buchem, M. A., van der Grond, J., Roos, R. A. C.


AJNR. American Journal Of Neuroradiology, Volume: 34, No.: 2, Pages.: 317-322

Year of Publication



Background and Purpose: MTI is a quantitative MR imaging technique that has recently demonstrated structural integrity differences between controls and patients with HD. Potentially, MTI can be used as a biomarker for monitoring disease progression. To establish the value of MTI as a biomarker, we aimed to examine the change in these measures during the course of HD.; Materials and Methods: From the Leiden TRACK-HD study, 25 controls, 21 premanifest gene carriers, and 21 patients with manifest HD participated at baseline and during a 2-year follow-up visit. Brain segmentation of the cortical gray matter, white matter, caudate nucleus, putamen, pallidum, thalamus, amygdala, and hippocampus was performed by using the automated tools FAST and FIRST in FSL. Individual MTR values were calculated from these regions, and MTR histograms were constructed.; Results: In the premanifest HD group stage “far from disease onset,” a significant increase in MTR peak height of the putamen was observed with time. During the manifest HD stage, neither the mean MTR nor the MTR peak height showed a significant change during a 2-year follow-up.; Conclusions: MTI-derived measures are not suitable for monitoring in Huntington disease during a 2-year period because there was no decrease in structural integrity detected in any of the manifest HD groups longitudinally. The finding of increased putaminal MTR peak height in the premanifest far from disease onset group could relate to a predegenerative process, compensatory mechanisms, or aberrant development but should be interpreted with caution until future studies confirm this finding.;

Bibtex Citation

@article{van_den_Bogaard_2012, doi = {10.3174/ajnr.a3303}, url = {}, year = 2012, month = {aug}, publisher = {American Society of Neuroradiology ({ASNR})}, volume = {34}, number = {2}, pages = {317--322}, author = {S. J. A. van den Bogaard and E. M. Dumas and E. P. Hart and J. Milles and R. Reilmann and J. C. Stout and D. Craufurd and C. R. Gibbard and S. J. Tabrizi and M. A. van Buchem and J. van der Grond and R. A. C. Roos}, title = {Magnetization Transfer Imaging in Premanifest and Manifest Huntington Disease: A 2-Year Follow-Up}, journal = {American Journal of Neuroradiology} }


adult, amygdala, assessment, basal ganglia, brain, cerebral cortex, disease, disease progression, genetics, hippocampus, humans, huntington disease, longitudinal studies, magnetic resonance imaging, methods, middle aged, of, pathology, progression, thalamus

Countries of Study


Types of Dementia


Types of Study

Non randomised controlled trial

Type of Outcomes


Type of Interventions

Diagnostic Target Identification

Diagnostic Targets

Neuroimaging (e.g. MRI, PET, CAT etc.)